C
7.81
-0.85 (-9.82%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Cullinan Therapeutics, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
1.5
| 分析师共识 | 5.0 |
| 内部交易活动 | 3.0 |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | 0.5 |
| 平均 | 1.50 |
|
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 4.55% |
| 机构持股比例 | 116.27% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 32.00 (BTIG, 309.73%) | 购买 |
| 中 | 28.00 (258.52%) | |
| 低 | 24.00 (HC Wainwright & Co., 207.30%) | 购买 |
| 平均值 | 28.00 (258.52%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 6.98 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 12 Sep 2025 | 24.00 (207.30%) | 购买 | 6.53 |
| 21 Aug 2025 | 24.00 (207.30%) | 购买 | 7.67 | |
| BTIG | 10 Sep 2025 | 32.00 (309.73%) | 购买 | 6.47 |
| Morgan Stanley | 18 Aug 2025 | 28.00 (258.51%) | 购买 | 7.95 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| LYNX1 CAPITAL MANAGEMENT LP | 8.49 | - | 165,667 | 1,406,513 |
| 累积净数量 | 165,667 | |||
| 累积净值 ($) | 1,406,513 | |||
| 累积平均购买 ($) | 8.49 | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| LYNX1 CAPITAL MANAGEMENT LP | 28 Oct 2025 | 买 (+) | 165,667 | 8.49 | 1,406,513 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合